Susquehanna International Group, LLP Cue Biopharma, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$1.24 - $2.18 $106,723 - $187,626	86,067 Added 255.73%	119,722 $148,000
Q1 2024 May 07, 2024	BUY	$1.77 - $3.09 $34,984 - $61,073	19,765 Added 142.3%	33,655 $63,000
Q4 2023 Feb 14, 2024	SELL	$1.72 - $3.1 $101,225 - $182,441	-58,852 Reduced 80.91%	13,890 $36,000
Q3 2023 Nov 14, 2023	BUY	$2.23 - $4.69 $15,781 - $33,191	7,077 Added 10.78%	72,742 $167,000
Q2 2023 Aug 11, 2023	SELL	$3.11 - $4.91 $207,965 - $328,331	-66,870 Reduced 50.45%	65,665 $239,000
Q1 2023 May 16, 2023	BUY	$2.41 - $3.74 $319,409 - $495,680	132,535 New	132,535 $473,000
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $304,256 - $459,796	-136,438 Reduced 82.68%	28,573 $64,000
Q2 2022 Aug 15, 2022	BUY	$2.49 - $5.92 $234,784 - $558,202	94,291 Added 133.33%	165,011 $411,000
Q1 2022 May 16, 2022	BUY	$4.41 - $12.28 $102,382 - $285,092	23,216 Added 48.87%	70,720 $345,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $203,049 - $333,741	18,697 Added 64.9%	47,504 $537,000
Q3 2021 Nov 15, 2021	SELL	$10.06 - $15.3 $164,048 - $249,497	-16,307 Reduced 36.15%	28,807 $420,000
Q2 2021 Aug 11, 2021	SELL	$10.9 - $14.53 $123,638 - $164,813	-11,343 Reduced 20.09%	45,114 $526,000
Q1 2021 May 17, 2021	BUY	$11.2 - $16.09 $372,052 - $534,493	33,219 Added 142.95%	56,457 $689,000
Q4 2020 Feb 16, 2021	SELL	$11.12 - $16.4 $79,641 - $117,456	-7,162 Reduced 23.56%	23,238 $291,000
Q3 2020 Nov 16, 2020	BUY	$15.05 - $23.54 $118,202 - $184,883	7,854 Added 34.84%	30,400 $458,000
Q2 2020 Aug 14, 2020	BUY	$12.7 - $30.73 $286,334 - $692,838	22,546 New	22,546 $553,000

Others Institutions Holding CUE

# of Institutions

Shares Held

14.1M

Call Options Held

14.4K

Put Options Held

2.6K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $43.5M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account